Literature DB >> 31441978

Time-resolved three-dimensional technique for dynamic magnetic resonance dacryocystography.

Paul I Sia1, David Curragh1, Sandy Patel1, Saul Rajak1, Peter Drivas1, Dinesh Selva1.   

Abstract

IMPORTANCE: This study introduces a new technique in the assessment of nasolacrimal drainage with magnetic resonance imaging.
BACKGROUND: To describe a new dynamic magnetic resonance dacryocystography (MRDCG) protocol and report normative findings on asymptomatic lacrimal drainage systems.
DESIGN: A prospective observational study at the Royal Adelaide Hospital. PARTICIPANTS: Seventeen patients with unilateral epiphora were prospectively recruited.
METHODS: Patients underwent dynamic MRDCG. The time-resolved angiography with interleaved stochastic trajectories (TWIST) sequence was used to visualise contrast flow through the lacrimal drainage system. MAIN OUTCOME MEASURES: Tear transit times and anatomical dimensions were measured.
RESULTS: Dynamic MRDCG with TWIST sequence reliably demonstrated contrast flow. Tear transit times and anatomical dimensions were comparable to previously reported values in other imaging modalities. CONCLUSIONS AND RELEVANCE: Dynamic MRDCG provides good structural and temporal resolution to the assessment of lacrimal outflow obstructions. The physiological nature of this modality allows potential assessment for functional obstruction and future research on tear flow assessment.
© 2019 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  epiphora; magnetic resonance dacryocystography; nasolacrimal duct obstruction

Year:  2019        PMID: 31441978     DOI: 10.1111/ceo.13618

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  1 in total

1.  Congenital lacrimal fistulas with secondary infection mimicking acute dacryocystitis: a case report and literature review.

Authors:  Pei-Fang Xu; Xin-Cao Zhong; Xin Shi; Juan Ye; Han Wu
Journal:  Int J Ophthalmol       Date:  2022-06-18       Impact factor: 1.645

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.